Easton Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in designing, developing, marketing, and selling of a range of topical drugs and therapeutic and cosmetic healthcare products. The company’s focus is on providing treatment and relief for certain types of cancer and other health issues related to female and male sexual dysfunction, stretch marks, scars, varicose veins, cellulite, pain, wounds, and other conditions.
The proprietary gel formulation of Easton Pharmaceuticals is a unique, innovative transdermal delivery system, a technology that allows for fast and effective development of naturally-derived, non-invasive topical solutions that promote healing of a variety of tissue and skin conditions through targeted delivery of active ingredients, herbs, and vitamins through the skin to the underlying tissue. Through transdermal delivery system, the company has developed an effective and safe female sexual enhancement product.
Easton Pharmaceuticals, Inc. is traded in the OTC market under the stock symbol EAPH. The goal of the company is to utilize their transdermal delivery system for rapid development and commercialization of their portfolio of products, which target a variety of tissue and skin conditions.
Easton Pharmaceuticals, Inc. is headquartered n Toronto, Canada and was founded on February 4, 1997 by John K. Easton. The company’s leaders are Carla Pepe, President, CEO & Director; Kent Deuters, Chief Operating Officer; John Adams, Chief Financial Officer & Director; Jack Barkin, Chief Medical Officer & Senior VP; and John Mitchell, VP for Business Development.
Easton Pharmaceuticals, Inc.
425 University Ave
Toronto, ONT M5G1T6
Phone: (416) 619-0291
Websites: http://www.eastonpharma.com/ and http://www.eastonpharmaceuticalsinc.com/
Yahoo! Finance: EAPH News
Latest Financial News for EAPH
TORONTO, June 13, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Easton Pharmaceuticals Inc. (OTC: EAPH) (“Easton” or “the Company”) announces it has filed its quarterly report for the three months ended March 31, 2019, and provides several key updates on its business initiatives. In the first quarter of 2019, Easton Pharmaceuticals recorded revenues of $612,689 and turned from a loss to post net income of $7,878. Revenues were generated from the Company’s contract with a prominent developer to frame 150 new homes in Whitby, Ontario, Canada, under its newly created real estate development division.
TORONTO, ON / ACCESSWIRE / April 30, 2019 / Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) executive management is pleased to announce the move of its corporate head office from Elm Street, Toronto, Ontario to Brockhouse Road, Toronto, Ontario. Easton confirms that with the acquisition of Supreme Sweets Inc. the management will be joining the Easton team at the Brockhouse Road facility and adding the extensive product line up to its growing product group within the Company's Food and Beverage operation. This move will allow Easton to oversee their Food & Beverage, Real Estate and Gaming all within the same physical premises.
TORONTO, ON / ACCESSWIRE / April 24, 2019 / Easton Pharmaceuticals, Inc. (the "Company" or "Easton") (OTC PINK: EAPH) is pleased to announce that it has now officially closed on its acquisition of a food processing company based in Toronto, Canada. Easton has completed its acquisition of Supreme Sweets Inc. and 2498411 Ontario Inc. (collectively the "Acquiree"), which includes all the tangible and intangible assets of the company such as equipment, intellectual property (patents, trade secrets, formulas, etc.) and client lists of both Supreme Sweets Inc. and 2498411 Ontario Inc. The purchase was completed with a combination of cash and Easton stock.
TORONTO, ON / ACCESSWIRE / April 12, 2019 / Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) provides update on the closing of its agreement to acquire a commercial bakery with existing revenues and projected to reach over $20,000,000 within 12 months. Easton announced earlier this week that its legal counsel believed that all documents would be completed this week with signatures and exchange of documents. Easton is acquiring a revenue generating commercial bakery and food preparation company in Toronto, Ontario, Canada.
TORONTO, ON / ACCESSWIRE / April 8, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) provides update on the closing of its agreement to acquire a commercial bakery with existing revenues and projected to reach over $20,000,000 within 12 months. Easton announced earlier in March that it had signed a Definitive Agreement to acquire a commercial bakery and food preparation company with existing revenues and projected revenues in excess of $20,000,000 over the next 12 months. Easton's legal counsel believes that all documents will be completed this week with signatures and exchange of documents.